Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulfasalazine for Decreasing Opioid Requirements in Breast Cancer Pain
NCT03847311Phase 2Completed
- Sponsor
- University of Arizona
- Start
- May 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 5-aminosalicylic acid + sulphasalazine in Malignancy-related chronic pain (2 arms), sponsored by University of Arizona. Primary endpoint: Overall Pain Relief at 12 weeks. Started May 2021; status: completed.
02
Drugs
5-aminosalicylic acid + sulphasalazine
03
Conditions
Malignancy-related chronic pain
Beyond the preview
Go deeper on NCT03847311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03847311.